University of California, Davis
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of California, Davis sits in the top decile of US sponsors by registered trial count (#52 of 15,742 sponsors by registered trial count).
University of California, Davis: 657 sponsored US clinical trials, 123 recruiting.
University of California, Davis sponsors 657 registered US clinical trials on ClinicalTrials.gov, 123 of them currently recruiting, and 435 completed. 38 of these trials are in Phase 3-4 (later-stage) and 129 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 12 trials.
Top-decile sponsor footprint
University of California, Davis ranks in the top decile of sponsors by registered trial count (#52 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
435 of 483 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
657 total, page 6 of 14
Healthy Planet Hepatitis B
NCT04503993
Interactions Between Skincare Product Ingredients and the Skin Microbiome
NCT04476732
Aesthetic Outcome of Electrodesiccation and Curettage vs Excision With Complex Linear Closure
NCT05074225
Exercise Study Testing Enhanced Energetics of Mitochondria Video Integrated Delivery of Activity Training in CKD
NCT02923063
Aesthetic Outcome of Running Cuticular Suture Distance (2mm vs 5mm)
NCT04870008
The Acute Effect of Mango Intake (Mangifera Indica L.) on Blood Pressure and Blood Glucose
NCT04057495
Effect of Cardiac Resynchronization Therapy (CRT) on Left Ventricular Assist Device (LVAD) Function
NCT04153786
Evaluation of Multi-Organ Metabolism and Perfusion in NAFLD by Total Body Dynamic PET Scan on EXPLORER
NCT04165343
Improving Critical Congenital Heart Disease Screening With Addition of Perfusion Measurements
NCT04056104
Pilot Study of Connected Diabetes Technology
NCT04106440
The Development and Effectiveness of Museum-Based Experiences for Individuals With Chronic Pain
NCT04091893
FamilyLink and Breastfeeding
NCT03957941
Evaluation of a Two-tiered Cross-age Teaching Model for Food Literacy-based Education
NCT04098419
Pre-operative Consultation on Patient Anxiety and First-time Mohs Micrographic Surgery
NCT04612491
Influence of Walnut Intake on Vascular Function and Metabolism
NCT03900403
SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer
NCT04050085
Development of a Marker of Adherence for Tracking Consumption of Nutrient Supplements
NCT04040543
LIFT: Telemedicine Breastfeeding Support
NCT03901833
Parametric PET of Genitourinary Cancer
NCT04020978
EXPLORER PET/CT in Healthy Volunteers
NCT04110743
External Fixation Versus Splinting of Acute Calcaneus Fractures
NCT04063657
The Effect of Gojiberry Intake (Lycium Barbarium) on Macular Function
NCT03983525
Effects of Brain Stimulation on Higher-Order Cognition
NCT03814967
Prospective Randomized Trial of Monocryl Versus Nylon Suture Closure in Carpal Tunnel Surgery
NCT03950401
The Effects of Dietary Fiber on the Gut Microbiome and HDL Particles of Human Subjects
NCT03785860
Use of a Distal Colonoscope Attachment to Increase Detection of Sessile Serrated Adenomas
NCT03560037
Cervical Preparation With Mifepristone Prior to Osmotic Dilators
NCT03714880
Massive Individualized N-of-1 Experiments (MINEs)
NCT03695263
Blocking Mifepristone Action With Progesterone
NCT03774745
Effect of Diastolic Dysfunction on Dynamic Cardiac Monitors
NCT04177225
Methylsulfonylmethane on Knee Laxity
NCT03747198
Opioid Use in Shoulder Arthroplasty Patients: A Stratification and Algorithm
NCT03808025
Phosphodiesterase 4 Inhibitor, Roflumilast, and the Effects of Inhibition in Severe Asthma
NCT04108377
Applying Prechtl's Assessment of General Movements for Preterm Infants Through Telemedicine
NCT03742635
The Cosmetic Effect of Mineral Clay Masks
NCT05041465
Perioperative Analgesia Using Gabapentin in Head and Neck Cancer Surgery
NCT03682367
Improving HPV Vaccination Rates Among Rural and Native American Adolescents
NCT03801603
Young Adult Beverage and Health Study
NCT03814551
Behavioral Family Therapy and Type One Diabetes
NCT03720912
The Effect of Almonds on Facial Aesthetics and Modulation of the Microbiome and Lipidome
NCT03729700
Integrating Behavioral Treatment in Primary Care
NCT03658122
The Probiotic for Oral Health (PRO Health) Study
NCT03748017
The Effect of CrossFit Kids on Social Skills in Children With Autism Spectrum Disorder (CrossFit KAMP)
NCT03693313
Sucrose-sweetened Beverage in African-American and Caucasian Women.
NCT03611972
Reducing Sugar-sweetened Beverage Consumption Among Young Adults
NCT03672578
Koa Family: California's Obesity Prevention Project
NCT03605888
Influence of Mango Intake of Skin Health in Postmenopausal Women
NCT03590756
Pilot Study: A Telehealth Intervention for Caregivers of Infants With Early Signs of Autism Spectrum Disorder
NCT03592654
The Influence of Oral Probiotics on the Microbiome and Lipidome
NCT03605108
Reproductive Health Outcomes by Method of Breast Milk Feeding
NCT03568851
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 86 |
| Phase 2 | 43 |
| Phase 3 | 10 |
| Phase 4 | 28 |
Therapeutic Areas
What is open in the University of California, Davis pipeline
123 recruiting of 657 indexed (19% open); 435 completed (66%).
Phase mix: 38 late (III/IV) vs 129 early (I/II) (early-phase heavy).
Top condition: Healthy (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of California, Davis: open-pipeline peers nationwide
Peers matched on 657 registered trials and 19% open enrollment, not the therapeutic-area sidebar.
University of California, Davis sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 657 trials (± recruiting share)
- Vanderbilt University Medical Center · 677 trials · 19% recruiting
- University of Rochester · 636 trials · 15% recruiting
- US Department of Veterans Affairs · 632 trials · 0% recruiting
- The Cleveland Clinic · 688 trials · 14% recruiting
Sponsors near 19% open enrollment (± trial volume)
- EyePoint Pharmaceuticals · 19% recruiting · 16 trials
- Hebrew SeniorLife · 19% recruiting · 32 trials
- Insulet Corporation · 19% recruiting · 16 trials
- Medical University of South Carolina · 19% recruiting · 755 trials
Related
What to do with this University of California, Davis page
657 registered trials is a research-attention snapshot, not an endorsement of University of California, Davis or any single study.
- 123 of University of California, Davis's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition University of California, Davis studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, Davis pipeline card: 657 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.